D-070

N-Desmethylolanzapine-d₈ dihydrochloride solution

100 μg/mL in acetonitrile: water (1:1) (as free base), ampule of 1 mL, certified reference material, Cerilliant^®

• 別名: N-Desmethylolanzapine-D₈ dihydrochloride solution
• 実験式（ヒル表記法）: C₁₆D₈H₁₀N₄S · H₂Cl₂
• 分子量: 379.38
• UNSPSCコード: 41116107
• NACRES: NA.24

特性

• グレード: certified reference material
• 品質水準: 300
• 形状: liquid
• 特徴: Snap-N-Spike^®/Snap-N-Shoot^®
• 包装: ampule of 1 mL
• メーカー／製品名: Cerilliant^®
• 濃度: 100 μg/mL in acetonitrile: water (1:1) (as free base)
• テクニック: gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• アプリケーション: clinical testing
• フォーマット: single component solution
• 保管温度: 2-8°C

詳細

詳細

A stable-labeled internal standard for use in LC/MS or GC/MS applications including clinical toxicology analysis, therapeutic drug monitoring, or isotope dilution methods. Desmethylolanzapine is the primary metabolite of olanzapine, marketed as the atypical antipsychotic Zyprexa^® for the treatment of schizophrenia and bipolar disorder.

アプリケーション

• Monitoring Metabolic Parameters in Schizophrenia: A study utilized plasma levels of olanzapine and its metabolite, N-desmethyl-olanzapine, to monitor metabolic parameters in patients with schizophrenia, providing a critical link between antipsychotic drug concentrations and metabolic health. This research supports the use of these biomarkers in clinical settings to optimize therapeutic strategies and manage side effects (Lu et al., 2018).


• Evaluating Clinical Efficacy in Schizophrenia: Another significant study applied plasma levels of olanzapine and N-desmethyl-olanzapine to assess clinical efficacy in schizophrenia patients. By correlating drug levels with therapeutic outcomes, this approach aids in personalized medicine, ensuring patients receive optimal dosages for effective treatment (Lu et al., 2016).

法的情報

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Zyprexa is a registered trademark of Eli Lilly and Co.

安全性情報

• ピクトグラム: GHS02,GHS07
• シグナルワード: Danger
• 危険有害性情報: H225,H302,H319
• 注意書き: P210 - P233 - P240 - P241 - P301 + P312 - P305 + P351 + P338
• 危険有害性の分類: Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2
• 保管分類コード: 3 - Flammable liquids
• WGK: WGK 2
• 引火点(°F): 55.4 °F - closed cup
• 引火点(℃): 13 °C - closed cup